Characteristic

Pulsar

Spectra

Stellar

Zenith

Primary endpoint

PVR reduction

Peak VO₂ increase

6 MWD improvement

Composite of death, transplant, or hospitalization

6 MWD change

+ 29.4 m (0.3 mg vs. placebo)

Improved (secondary)

+ 34.4 m vs. +1.0 m placebo (diff: ~ 40.8 m, p < 0.001)

Not specified

PVR change

-146 and -240 dyn·s·cm^⁻⁵ (0.3 and 0.7 mg)

Not specified

Not specified

Not specified

NT-proBNP

Reduced

Not specified

Not specified

Not specified

WHO-FC

Improved

Not specified

Not specified

Not specified

Peak VO₂

Not specified

+ 102.7 mL/min (p < 0.01)

Not specified

Not specified

RV function

Not specified

Improved

Not specified

Not specified

Clinical worsening

Not specified

Not specified

Not specified

17.4% vs. 54.7% (HR 0.24, p < 0.0001)

Secondary endpoints

Not specified

Not specified

8 of 9 favored Sotatercept

Not specified